JP2022516660A5 - - Google Patents
Info
- Publication number
- JP2022516660A5 JP2022516660A5 JP2021539621A JP2021539621A JP2022516660A5 JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5 JP 2021539621 A JP2021539621 A JP 2021539621A JP 2021539621 A JP2021539621 A JP 2021539621A JP 2022516660 A5 JP2022516660 A5 JP 2022516660A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- fusion antibody
- seq
- glb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789953P | 2019-01-08 | 2019-01-08 | |
| US62/789,953 | 2019-01-08 | ||
| PCT/US2020/012549 WO2020146359A1 (en) | 2019-01-08 | 2020-01-07 | Methods and compositions for increasing galactosidase beta-1 activity in the cns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516660A JP2022516660A (ja) | 2022-03-01 |
| JP2022516660A5 true JP2022516660A5 (https=) | 2023-01-06 |
Family
ID=71521947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539621A Pending JP2022516660A (ja) | 2019-01-08 | 2020-01-07 | ＣＮＳにおけるガラクトシダーゼβ－１活性を増加させるための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20210403584A1 (https=) |
| EP (1) | EP3908611A4 (https=) |
| JP (1) | JP2022516660A (https=) |
| WO (1) | WO2020146359A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| EP4526351A2 (en) * | 2022-05-16 | 2025-03-26 | City of Hope | Anti-cd84 antibodies and uses thereof |
| CN120035662A (zh) * | 2022-10-12 | 2025-05-23 | 新型医药公司 | 用于治疗、预防或改善GM1神经节苷脂沉积症或Morquio综合征B的药物组合物及其施用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082224A1 (en) * | 1997-01-14 | 2002-06-27 | Douglas J. Jolly | Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| CA2607133A1 (en) * | 2005-05-02 | 2006-11-09 | Toray Industries, Inc. | Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer |
| CA2641070C (en) * | 2006-02-06 | 2017-01-03 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
| US9388425B2 (en) * | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| CA2748889A1 (en) * | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| CA2840224C (en) * | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| WO2013052915A2 (en) * | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
-
2020
- 2020-01-07 US US17/295,390 patent/US20210403584A1/en not_active Abandoned
- 2020-01-07 JP JP2021539621A patent/JP2022516660A/ja active Pending
- 2020-01-07 WO PCT/US2020/012549 patent/WO2020146359A1/en not_active Ceased
- 2020-01-07 EP EP20738170.8A patent/EP3908611A4/en not_active Withdrawn
-
2025
- 2025-01-28 US US19/039,422 patent/US20250179201A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2022518392A5 (https=) | ||
| JP2021508449A5 (https=) | ||
| JP2021512881A5 (https=) | ||
| JP2023504914A5 (https=) | ||
| JP2022516660A5 (https=) | ||
| JP2013537416A5 (https=) | ||
| JP2016525545A5 (https=) | ||
| JP2015509097A5 (https=) | ||
| JP2010539921A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP7449092B2 (ja) | 血液脳関門移動化合物及びその使用 | |
| JP2008500373A5 (https=) | ||
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| TW202334429A (zh) | Sars-cov-2棘蛋白特異性抗體及其用途 | |
| JP2021512159A5 (https=) | ||
| JP2008515889A5 (https=) | ||
| JP2008521426A5 (https=) | ||
| JP2023552462A5 (https=) | ||
| US20240270797A1 (en) | Coronavirus neutralizing compositions and associated methods | |
| JP2024501771A5 (https=) | ||
| RS55133B1 (sr) | Antigen vezujući proteini specifični za p komponentu amiloida seruma | |
| JP2017524675A5 (https=) | ||
| JP2021533167A5 (https=) | ||
| JP7804590B2 (ja) | 抗ｉｌ－３３抗体の処方物 |